Trudy Mackay, renowned “genomic scientist” will gather a team of researchers to advance the understanding of genetic disorders.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
GMI announces new cross-border research collaboration that aims to identify genetic markers, to help diagnose and treat Multiple Sclerosis (MS).
Chinese chemical manufacturing firm Boai NKY Pharmaceuticals plans to purchase BioVision Inc., a drug screening specialist headquartered in San Francisco.
An adapted CRISPR technique could be used to treat incurable diseases, such as diabetes and muscular dystrophy, by turning up the volume on selected genes.
Researchers from the University of Michigan have identified a vicious cycle of toxic protein production set in motion by cell stress that contributes to ALS
A potentially new treatment that could delay or even prevent Alzheimer’s is being hotly pursued.
Two major pharma companies express concerns that attracting and retaining the right talent could still be a problem, following UK Government’s £1bn deal.
Spark Therapeutics’ gene therapy for patients with haemophilia has seen some early success in clinical trials, after being tested in 10 male patients
We caught up to Macrogen at ASHG, to speak about their latest CAP accreditation, and what benefits this will bring them in the next year.
The UK government has signed a deal with 25 global organisations that aims to boost life sciences research and investment in the UK.
As the year draws to a close, Rick Duprey, writing for The Motley Fool, takes a look back at three biotechs that have quadrupled this year.
Congress is working on a tax overhaul. But it turns out the tax bills in the House and Senate also aim to reshape health care.